Feds Remain Circumspect on Role of Device Firms in Value Arrangements

article image

The Trump administration has rolled out two proposed regulations intended to modernize kickback and self-referral protections for the value-based era, but there are still questions to be answered about exactly where device companies fit in.

Medtech firms were hoping for more legal assurances to support setting up value-based, risk-sharing contracts with hospitals and others in two proposed rules dropped by the Trump administration October 9.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: